Navigation Links
Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators
Date:7/1/2013

regulate the reconstitution of a specialized bacteria-responsive subset of immune cells after HCT, and that impaired regulation of this immune cell subset is associated with an increased risk of infection or GVHD.

Dr. Turtle works under the mentorship of Stanley R. Riddell, MD, at Fred Hutchinson Cancer Research Center, Seattle, Washington.

2013 Clinical Investigator Continuation Grants

Tobias Carling, MD, PhD

Dr. Carling focuses on endocrine tumors, a type of cancer that affects hormone-producing tissues in the body (such as the thyroid, pituitary gland, adrenal gland and islet cells of the pancreas). The underlying genetic basis for endocrine tumors is not yet known. Dr. Carling's goal is to complete a comprehensive genomic analysis of patients with endocrine tumor disease in order to identify individual genes involved in early cancer formation. The Continuation Grant will be used to further these studies on endocrine tumors and also characterize thyroid and adrenal cancers. He aims to use these findings to develop improved strategies for personalized medical and surgical treatment of cancer patients.

Dr. Carling works under the mentorship of Richard P. Lifton, MD, PhD, and Robert Udelsman, MD, MBA, at Yale University School of Medicine, New Haven, Connecticut.

N. Lynn Henry, MD, PhD

Due to advances in cancer screening and treatments, the majority of women diagnosed with breast cancer will be cured of their disease. However, many will require at least five years of therapy with medications called aromatase inhibitors, which greatly reduce the amount of estrogen circulating in the body. These drugs cause new or worsening aches and pains in about half of women taking them, resulting in decreased quality of life.

The overall goal of this project is to obtain a better understanding of why some patients with breast cancer develop treatment-related pain. Dr. Henry [Damon Runyo
'/>"/>

Contact: Yung S. Lie
yung.lie@damonrunyon.org
212-455-0521
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology news :

1. Damon Runyon Cancer Research Foundation grants prestigious awards to 17 young scientists
2. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
3. ACRG and BGI report new evidence for the genetic bases of liver cancer
4. Cancer is a result of a default cellular safe mode, physicist proposes
5. Continued research needed on treatment for women with lung cancer who are never smokers
6. TGen and Ventana Medical Systems Inc. join forces to fight cancer
7. National Institutes of Health to fund research probing proteins linked to cancer, diabetes
8. Herding cancer cells to their death
9. No danger of cancer through gene therapy virus
10. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
11. Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... dangerous consequences of iron deficiencies is the fact that ... origin of the genetic iron overload disorder hereditary ... researchers from the European Molecular Biology Laboratory (EMBL) and ... HH is a liver disease. They report in the ...
... PITTSBURGH Scientists at Carnegie Mellon Universitys Molecular Biosensor ... proteins (FAPs) that will become a key component ... Carnegie Mellon. The FAPs, which can be used ... other biomolecules within living cells in real time, ...
... bisporus) has as much, and in some cases, more anti-oxidant ... is the foremost cultivated edible mushroom in the world with ... thought of as a poor relation to its more exotic ... But according to new research in SCIs Journal of the ...
Cached Biology News:Europe's most common genetic disease is a liver disorder 2Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design 2Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design 3
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)...  Pomerantz LLP announces that a class action lawsuit ... the "Company")(NYSE: PBYI ) and certain of its ... Court, Central District of California , ... class consisting of all persons or entities who purchased ... 2015 inclusive (the "Class Period").  This class action seeks ...
(Date:7/2/2015)... July 2, 2015 Amici Procurement ... procurement company Amici Procurement has chosen Microsoft Cloud Solution ... move to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) ... to medium-sized companies in the bio-tech sector with a ... the purchasing cycle to help them obtain best value. ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Biotech Procurement Company Moves to Office 365 with iomart 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... NEW YORK, Aug. 11 /PRNewswire-Asia-FirstCall/ ... ("the Company" or "AOBO"), a pharmaceutical,company dedicated to improving ... range of prescription and over the counter ("OTC"),products in ... Board of,Directors of AOBO approved the engagement of Ernst ...
... , , SEATTLE, Aug. 11 ... 2 clinical trial of OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) ... anti-inflammatory agent and an agent that causes pupil dilation ... , Omeros, Phase 1/Phase 2 trial ...
... , , , COLUMBIA, Md., ... MATK ), today announced the signing of a Joint Development Agreement ... applications. The partnership combines a broad technology platform and operational capabilities ... of sugars into biodiesel. , , Under ...
Cached Biology Technology:Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4